JP2017165661A - Carbohydrate metabolism improver - Google Patents
Carbohydrate metabolism improver Download PDFInfo
- Publication number
- JP2017165661A JP2017165661A JP2016050276A JP2016050276A JP2017165661A JP 2017165661 A JP2017165661 A JP 2017165661A JP 2016050276 A JP2016050276 A JP 2016050276A JP 2016050276 A JP2016050276 A JP 2016050276A JP 2017165661 A JP2017165661 A JP 2017165661A
- Authority
- JP
- Japan
- Prior art keywords
- glucose
- buttermilk
- carbohydrate metabolism
- carbohydrate
- metabolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000023852 carbohydrate metabolic process Effects 0.000 title claims abstract description 25
- 235000021256 carbohydrate metabolism Nutrition 0.000 title claims abstract description 25
- 235000015155 buttermilk Nutrition 0.000 claims abstract description 55
- 239000008103 glucose Substances 0.000 claims abstract description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 19
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 13
- 230000002496 gastric effect Effects 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 230000004153 glucose metabolism Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000004190 glucose uptake Effects 0.000 abstract description 3
- 235000020247 cow milk Nutrition 0.000 abstract description 2
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 230000000378 dietary effect Effects 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 235000014121 butter Nutrition 0.000 description 5
- 235000021258 carbohydrate absorption Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000021243 milk fat Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091006277 SLC5A1 Proteins 0.000 description 2
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108010071421 milk fat globule Proteins 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Landscapes
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、乳由来のバターミルクを有効成分として含有する糖質代謝改善剤に関する。詳しく言うと、本発明は、バターミルクを有効成分とする腸管上皮細胞での糖質吸収抑制に関するものであって、ヒトを含む哺乳動物等の組織細胞のうち、腸管上皮細胞での糖質の取り込みを抑制する作用を持つ糖質吸収抑制剤、あるいは、バターミルクを配合して腸管上皮細胞での糖質取り込みの抑制作用を付加した飲食品などの用途に関するものである。 The present invention relates to a carbohydrate metabolism improving agent containing buttermilk derived from milk as an active ingredient. Specifically, the present invention relates to suppression of carbohydrate absorption in intestinal epithelial cells containing buttermilk as an active ingredient, and among the tissue cells of mammals including humans, the carbohydrates in intestinal epithelial cells The present invention relates to a use of a carbohydrate absorption inhibitor having an action of suppressing uptake, or a food or drink to which buttermilk is added to add an action of suppressing the uptake of sugar in intestinal epithelial cells.
近年、食生活の乱れや慢性的な運動不足、過度のストレスなどにより、肥満や高血圧、高脂血、糖尿病などの生活習慣病に対するリスクの増加が問題となっている。これらの生活習慣病の症状が進行すると動脈硬化や心筋梗塞など、より重篤な病気を引き起こすことになる。生活習慣病の原因のうち、食生活の乱れについては、日本人の食生活が欧米的なものに変化し、従来の日本食に比べ非常に高カロリーな食事なものとなっていることが大きな要素となっている。高カロリーの食生活は、肥満を引き起こしやすく、肥満はさまざまな生活習慣病を引き起こすことが報告されている。肥満になると、糖尿病を発症する危険性の高い糖尿病予備軍となる可能性が高いとされている。
糖尿病になると、空腹状態時またはブドウ糖付加試験中にグルコース投与後の血漿グルコースレベルが高くなる。すなわち高血糖が持続し、血糖値が正常にコントロールされない状態となる。このようにグルコースの恒常性の維持が異常であると、脂質、リポタンパク質、アポリポタンパク質代謝が変化し、その他の代謝異常および血行動態的疾患が発症する。よって、糖尿病患者は、冠状心疾患、脳卒中、抹消血疾患、高血圧、腎症、神経障害、網膜症を含めた大血管および微小血管合併症を併発する危険性が健常者と比較して顕著に高い。したがって、糖尿病を臨床的に管理および治療するときは、グルコースホメオスタシス、脂質代謝および血圧をコントロールすることが重要である。
糖尿病には、インスリン依存の有無によって１型と２型の２つの型があることが認められ
ている。１型糖尿病、すなわちインスリン依存性糖尿病では、膵臓のβ細胞が破壊される
事が原因とされ、１型糖尿病患者はグルコース利用を調節するホルモンであるインスリン
をほとんど生成しない。２型糖尿病、すなわちインスリン非依存性糖尿病では、遺伝的体
質に肥満が加わり発症すると言われ、血漿インスリンレベルが健常なヒトと比較して同等かまたは高いことが多い。しかしながら、これら２型糖尿病の患者は主なインスリン感受
性組織である筋肉、肝臓や脂肪組織におけるグルコースおよび脂質代謝に対するインスリン刺激作用に対して抵抗性を有している。したがって、血漿インスリンレベルは高いにも関わらず、顕著なインスリン抵抗性の為にインスリンが正常に働くことが出来ない。
糖尿病は、前記の通りさまざまな合併症を引き起こす原因とされており、糖尿病を予防するためにさまざまな試みがなされている。その結果、糖尿病を予防することを目的とした食品用の成分が提案されており、食後の血糖値上昇抑制作用を有する物質等が報告されている。
例えば、腸管から糖の吸収を抑制する成分としては、α−アミラーゼ阻害剤、グリコシダーゼ阻害剤などの糖分解酵素の阻害作用を有する成分、食物繊維などの腸管から糖の吸収抑制作用がある成分が報告されている。（特許文献１，２）
また、上記以外にも酵素阻害ではないが糖の消化管からの吸収を遅延させて血糖値の上昇を抑制する成分、例えば、難消化性デキストリン、ガラクトマンナン、可溶性アルギン酸ナトリウム、イヌリンなどの食物繊維を例が報告されている。
In recent years, an increase in risk for lifestyle-related diseases such as obesity, hypertension, hyperlipidemia, and diabetes has become a problem due to disorder of eating habits, chronic lack of exercise, and excessive stress. The progression of these lifestyle-related diseases causes more serious diseases such as arteriosclerosis and myocardial infarction. Among the causes of lifestyle-related diseases, a major factor for the disorder in eating habits is that the Japanese eating habits have changed to Western ones, resulting in a meal that is much higher in calories than traditional Japanese food. It has become. A high-calorie diet is prone to obesity, which has been reported to cause various lifestyle-related diseases. Obesity is likely to be a diabetic reserve with a high risk of developing diabetes.
When diabetic, plasma glucose levels are higher after administration of glucose during fasting or glucose supplementation tests. That is, hyperglycemia persists and the blood glucose level is not normally controlled. Thus, if the maintenance of glucose homeostasis is abnormal, lipid, lipoprotein, and apolipoprotein metabolism change, and other metabolic abnormalities and hemodynamic diseases develop. Therefore, diabetic patients are significantly more at risk of developing coronary heart disease, stroke, peripheral blood disease, hypertension, nephropathy, neuropathy, and macrovascular and microvascular complications compared to healthy individuals. high. Therefore, when clinically managing and treating diabetes, it is important to control glucose homeostasis, lipid metabolism and blood pressure.
It is recognized that there are two types of diabetes, type 1 and type 2 depending on the presence or absence of insulin dependence. In type 1 diabetes, that is, insulin-dependent diabetes, it is caused by destruction of β cells of the pancreas, and type 1 diabetes patients hardly produce insulin, which is a hormone that regulates glucose utilization. Type 2 diabetes, that is, non-insulin-dependent diabetes, is said to develop with obesity in the genetic constitution, and plasma insulin levels are often the same or higher compared to healthy humans. However, these type 2 diabetic patients are resistant to insulin stimulating effects on glucose and lipid metabolism in muscle, liver and adipose tissues, which are the main insulin sensitive tissues. Therefore, despite high plasma insulin levels, insulin cannot work normally due to significant insulin resistance.
Diabetes is considered to cause various complications as described above, and various attempts have been made to prevent diabetes. As a result, food ingredients intended to prevent diabetes have been proposed, and substances having an inhibitory effect on postprandial blood glucose level have been reported.
For example, components that suppress the absorption of sugar from the intestinal tract include components that have an inhibitory action on glycolytic enzymes such as α-amylase inhibitors and glycosidase inhibitors, and components that have an action to suppress sugar absorption from the intestinal tract such as dietary fiber. It has been reported. (Patent Documents 1 and 2)
In addition to the above, components that are not enzyme inhibitors but delay the absorption of sugar from the gastrointestinal tract to suppress an increase in blood glucose level, such as dietary fibers such as indigestible dextrin, galactomannan, soluble sodium alginate, and inulin An example has been reported.
一方、バターミルクには、アルコール生成物代謝促進作用などの機能が明らかにされているが(特許文献３）、糖質の吸収改善に関することは知られていない。 On the other hand, buttermilk has been clarified in functions such as an alcohol product metabolism promoting action (Patent Document 3), but it is not known to improve carbohydrate absorption.
特許文献１、２に記載の糖の吸収抑制剤を得るには、植物からの抽出作業が必要であり工程が複雑である。そこで、複雑な工程を必要とせず、通常の食品としても利用されている糖質代謝改善促進剤が求められている。本発明は、これを摂取することで消化管上皮細胞からのグルコースの取り込みを抑制することができるバターミルクを有効成分とする糖質代謝改善剤、あるいは糖質代謝改善用飲食品を提供することを課題とする。 In order to obtain the sugar absorption inhibitor described in Patent Documents 1 and 2, extraction from plants is necessary and the process is complicated. Therefore, there is a need for a saccharide metabolism improvement promoter that does not require a complicated process and is also used as a normal food. The present invention provides a carbohydrate metabolism improving agent containing buttermilk, which can suppress glucose uptake from gastrointestinal epithelial cells by ingesting this, or a food and drink for improving carbohydrate metabolism. Is an issue.
本発明者らは、日常的に摂取が可能である食品素材によって生体の数々の機能異常を予防や改善できないかという観点で、乳または乳素材に着目し、鋭意検討を進めたところ、バターミルクが消化管上皮細胞からの糖質の取り込みを抑制する作用を見出し、本発明を完成するに至った。 即ち本発明は以下の構成を有する
（1）バターミルクを有効成分とする消化管上皮細胞から糖質の取り込みを抑制する糖質代謝改善剤
（2）バターミルクパウダーを還元したバターミルクを有効成分とする消化管上皮細胞から糖質の取り込みを抑制する糖質代謝改善剤
（3）バターミルクパウダーを有効成分とする消化管上皮細胞から糖質の取り込みを抑制する糖質代謝改善剤
（4）糖質の種類がグルコースであることを特徴とする（1）乃至（3）のいずれかに記載の糖質代謝改善剤
（5）（１）乃至（４）のいずれかに記載の糖質代謝改善剤を含むことを特徴とする糖質代謝改善用飲食品、糖質代謝改善用栄養組成物、または糖質代謝改善用医薬品。
（6）（１）乃至（５）のいずれかに記載の糖質代謝改善剤を経口摂取することによる糖質代謝改善方法。
The inventors of the present invention focused on milk or dairy materials from the viewpoint of preventing or improving various functional abnormalities of living organisms with food materials that can be ingested on a daily basis. Has found an action of suppressing the uptake of carbohydrates from gastrointestinal epithelial cells, and has completed the present invention. That is, the present invention has the following constitution: (1) a carbohydrate metabolism-improving agent that suppresses carbohydrate uptake from gastrointestinal epithelial cells containing buttermilk as an active ingredient (2) buttermilk obtained by reducing buttermilk powder as an active ingredient Glucose metabolism improving agent that suppresses carbohydrate uptake from gastrointestinal epithelial cells (3) Glucose metabolism improving agent that suppresses carbohydrate uptake from gastrointestinal epithelial cells containing buttermilk powder as an active ingredient (4) The carbohydrate metabolism improving agent according to any one of (1) to (3), wherein the carbohydrate type is glucose (5) The carbohydrate metabolism according to any one of (1) to (4) A food or drink for improving carbohydrate metabolism, a nutritional composition for improving carbohydrate metabolism, or a pharmaceutical product for improving carbohydrate metabolism, comprising an improving agent.
(6) A method for improving carbohydrate metabolism by orally ingesting the carbohydrate metabolism-improving agent according to any one of (1) to (5).
バターミルクを有効成分とする消化管上皮細胞への糖質の取り込みを抑制する糖質代謝改善剤や糖質代謝改善飲食品を提供出来る。本発明の糖質吸収抑制剤や糖質代謝改善飲食品は、これらを摂取することにより、消化管上皮細胞での糖質を抑制することで過剰な血糖値上昇を抑制することで、数々の生活習慣病の治療および予防に有効である。 It is possible to provide a carbohydrate metabolism-improving agent and a carbohydrate metabolism-improving food and drink that suppress the uptake of carbohydrates into gastrointestinal epithelial cells containing buttermilk as an active ingredient. The carbohydrate absorption inhibitor and the carbohydrate metabolism-improving food / beverage of the present invention, by ingesting these, suppress excessive glucose increase by suppressing carbohydrates in the gastrointestinal epithelial cells. It is effective in the treatment and prevention of lifestyle-related diseases.
乳等省令によると「バターミルク」とは、バターを製造する際に生じた脂肪粒以外の部分をいい、「バターミルクパウダー」とは、バターミルクからほぼ水分を除去し、乾燥させたものをいう。成分の規格は、バターミルクパウダーにおいて、乳固形分95%以上、水分5%以下と定められている。バターミルクは、乳脂肪分３０〜４０％に調製したクリームよりバターを製造する際に、チャーニングのような乳脂肪球同士の衝突による乳化破壊等の物理的分画操作より、目的とするバターと共に副産物として発生する淡黄色の液体である。また、クリームに乳酸菌を接種して発酵後、発酵バターを製造する際にもバターミルクを製造しており、これは、通常、酸性バターミルクと呼ばれている。一方、発酵しない工程によるものを甘性バターミルクと呼ぶ。本発明の対象は、この甘性、酸性バターミルクの種類を区別するものではない。バターミルクは、牛乳と同様に脂質、タンパク、炭水化物、ミネラル、ビタミン等を含有し、特にその製造方法からも分かるように、乳脂肪球の界面を構成する乳脂肪球皮膜物質が多く含まれているのが特徴であり、脂肪球皮膜タンパク質として、カゼイン、α−ラクトアルブミン、β−ラクトグロブリンの他、乳脂肪球皮膜物質特有のリポタンパク質、糖タンパク質、リン脂質の存在が知られている。
本発明の糖質代謝改善剤の有効成分であるバターミルクは、公知の方法でヒト、ウシ、水牛、ヤギ、ヒツジ等の哺乳類の乳から調製されたものや、市販されているバターミルクを使用することが可能である。例えば、バターミルクは、生乳から分離した脂肪分４０重量％以上のクリームや発酵クリーム、ホエイクリーム等を原料としてチャーン等を用いてチャーニング（剪断処理）することによって脂肪球を破壊・融合してバターを製造する際に排出される脂肪分１から１５重量％の水相成分として得ることができる。また、上記のように調製したバターミルクは、通常、食品や医薬品を製造する際に使用される熱等による殺菌処理をすること、ならびに凍結乾燥や噴霧乾燥等により乾燥することでバターミルクパウダーとしても使用可能である。よって、本出願でいうバターミルクには、水分以外の成分が同等であるバターミルクパウダーも含まれる。
According to the Ordinance of Milk, etc., “butter milk” refers to the portion other than the fat particles produced during the production of butter, and “butter milk powder” refers to a product obtained by removing almost all moisture from butter milk and drying it. Say. Ingredient standards for the buttermilk powder are defined as 95% or more of milk solids and 5% or less of moisture. When producing butter from a cream prepared with a milk fat content of 30 to 40%, butter milk is obtained from a physical fractionation operation such as demulsification due to collision between milk fat globules such as cherning. And a pale yellow liquid generated as a by-product. In addition, butter milk is also produced when fermenting butter after inoculating lactic acid bacteria in a cream, which is usually called acidic butter milk. On the other hand, a product that is not fermented is called sweet buttermilk. The subject of the present invention does not distinguish between the sweet and acidic buttermilk types. Buttermilk contains lipids, proteins, carbohydrates, minerals, vitamins, etc., like cow's milk, and contains many milk fat globule membrane substances that make up the interface of milk fat globules, as can be seen from its production method. As fat globule membrane proteins, the presence of casein, α-lactalbumin, β-lactoglobulin, lipoprotein, glycoprotein, and phospholipid peculiar to milk fat globule membrane material is known.
The buttermilk, which is an active ingredient of the saccharide metabolism improving agent of the present invention, is prepared from milk of mammals such as humans, cows, buffalos, goats and sheep by a known method, or commercially available buttermilk is used. Is possible. For example, buttermilk breaks and fuses fat globules by churning (shearing) with churn and the like using cream, fermented cream, whey cream, etc. with a fat content of 40% by weight or more separated from raw milk. It can be obtained as an aqueous phase component having a fat content of 1 to 15% by weight discharged when producing butter. In addition, the buttermilk prepared as described above is usually used as a buttermilk powder by being sterilized by heat or the like used in the production of foods and pharmaceuticals, and dried by freeze drying or spray drying. Can also be used. Therefore, the buttermilk referred to in the present application includes buttermilk powder in which components other than moisture are equivalent.
本発明の糖質代謝改善剤のバターミルクは、そのまま糖質代謝改善剤として使用してもよいが、必要に応じて、常法に従い製剤化して用いる事もできる。剤形としては、安定剤、賦型剤、結合剤、崩壊剤、滑沢剤、懸濁剤、コーティング剤、その他の任意の薬剤を混合した錠剤、カプセル剤、顆粒剤、散剤、粉末剤、シロップ剤等の製剤を例示することができる。また、さらに、バターミルク又はバターミルクを製剤化したものを栄養剤やヨーグルト、パン、スナック菓子、ケーキ、プリン、飲料、発酵乳、麺類、ソーセージ、各種粉乳や離乳食等の飲食品、栄養組成物及び医薬品に配合することも可能である。 The buttermilk, which is a saccharide metabolism improving agent of the present invention, may be used as it is as a saccharide metabolism improving agent, but if necessary, it can also be formulated and used according to a conventional method. The dosage form includes stabilizers, excipients, binders, disintegrants, lubricants, suspensions, coating agents, tablets mixed with any other drugs, capsules, granules, powders, powders, Formulations such as syrups can be exemplified. Furthermore, buttermilk or buttermilk formulated with nutrients, yogurt, bread, snack confectionery, cakes, pudding, beverages, fermented milk, noodles, sausages, various milk powders and baby foods, nutritional compositions and It can also be blended into pharmaceutical products.
以下に、実施例および試験例を示し、本発明についてより詳細に説明するが、これらは単に例示するのみであり、本発明はこれらによって何ら限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples. However, these are merely illustrative and the present invention is not limited thereto.
（バターミルクの製造）
生乳から分離したクリーム（脂肪分重量47％）10kgをメタルチャーンでせん断処理することにより、バターと水相画分であるバターミルクに分離した。このバターミルクを凍結乾燥して、バターミルク粉末（実施例品１）440ｇを得た。このバターミルクの粉末には、全乳固形分中、脂肪が7.3重量％、タンパク質が32.5重量％、炭水化物が52.5重量％、灰分が重量7.7％含まれていた。このようにして得られたバターミルク粉末は、そのまま本発明の糖質代謝改善剤として使用可能である。
(Manufacture of buttermilk)
10 kg of cream (fat weight: 47%) separated from raw milk was sheared with metal churn to separate into butter and buttermilk, which is an aqueous phase fraction. This buttermilk was freeze-dried to obtain 440 g of buttermilk powder (Example Product 1). This buttermilk powder contained 7.3 wt% fat, 32.5 wt% protein, 52.5 wt% carbohydrate, and 7.7 wt% ash in the total milk solids. The buttermilk powder thus obtained can be used as it is as the carbohydrate metabolism improving agent of the present invention.
＜試験例１＞
バターミルクの糖質代謝改善効果を試験した。
コラーゲンコートした24ウェルプレートにヒトグルコーストランスポーター（SGLT1）安定発現細胞株（東京大学で保有）を2.0×105/wellで播種し、1日培養した。培養後、10μCi/ml 3H-グルコース100μＬと実施例１で得られたバターミルク溶液100μＬを細胞に添加した後、30分間取り込み実験を行った。コントロール群は、3H-グルコースとエタノールを適量細胞に添加した。取り込み実験終了後、細胞を回収し、3H-グルコースの量を測定した。結果を図１に示す。
図１の横軸はバターミルクの濃度を、縦軸はコントロール群に対するバターミルクを添加した群の3H-グルコースの相対取り込み量（バターミルクを添加した群の取り込み量／コントロール群の取り込み量）を％で表す。図１より、バターミルク量が0.1重量%では取込抑制が見られなかったが、バターミルクが0.25重量％以上でグルコースの取り込み抑制が見られ、濃度の依存性も確認できた。したがって、本発明のバターミルクはグルコースの取り込み抑性機能を有し、糖質代謝改善剤として用いる事が出来る事が分かった。
<Test Example 1>
The effect of buttermilk on improving carbohydrate metabolism was tested.
A human glucose transporter (SGLT1) stable expression cell line (owned by the University of Tokyo) was seeded at 2.0 × 10 5 / well on a collagen-coated 24-well plate and cultured for 1 day. After the culture, 100 μL of 10 μCi / ml 3 H-glucose and 100 μL of the buttermilk solution obtained in Example 1 were added to the cells, and an uptake experiment was performed for 30 minutes. In the control group, 3 H-glucose and ethanol were added to the cells in appropriate amounts. After completion of the uptake experiment, the cells were collected and the amount of 3 H-glucose was measured. The results are shown in FIG.
The horizontal axis of FIG. 1 is the concentration of buttermilk, and the vertical axis is the relative uptake of 3 H-glucose of the group to which buttermilk is added relative to the control group (uptake of the group to which buttermilk is added / uptake of the control group). Is expressed in%. From FIG. 1, uptake suppression was not observed when the amount of buttermilk was 0.1% by weight, but uptake of glucose was observed when the buttermilk was 0.25% by weight or more, and the concentration dependence was also confirmed. Therefore, it was found that the buttermilk of the present invention has a glucose uptake-suppressing function and can be used as a carbohydrate metabolism improving agent.
（糖質代謝改善用カプセル剤の調製）
表１に示す配合で原材料を混合した後、常法により造粒し、ソフトカプセルに充填して、本発明の糖質吸収抑制用カプセル剤を製造した。
(Preparation of capsules for improving carbohydrate metabolism)
After mixing the raw materials with the formulation shown in Table 1, the mixture was granulated by a conventional method and filled into a soft capsule to produce a capsule for suppressing carbohydrate absorption according to the present invention.
（糖質代謝改善用錠剤の調製）
表２に示す配合で原材料を混合した後、常法により１ｇに成型、打錠して本発明の糖質代謝改善用錠剤を製造した。
(Preparation of tablets for improving carbohydrate metabolism)
After mixing the raw materials with the formulation shown in Table 2, it was molded into 1 g by a conventional method and tableted to produce a carbohydrate metabolism improving tablet of the present invention.
実施例品１のバターミルク５０ｇを４，９５０ｇの脱イオン水に溶解し、５０℃まで加熱後、ＴＫホモミクサー（ＴＫ ＲＯＢＯ ＭＩＣＳ；特殊機化工業社製）にて、６，０００ｒｐｍで３０分間撹拌混合して５０ｇ／５ｋｇのバターミルク溶液を得た。このバターミルク溶液５．０ｋｇに、カゼイン５．０ｋｇ、大豆タンパク質５．０ｋｇ、魚油１．０ｋｇ、シソ油３．０ｋｇ、デキストリン１７．０ｋｇ、ミネラル混合物６．０ｋｇ、ビタミン混合物１．９５ｋｇ、乳化剤２．０ｋｇ、安定剤４．０ｋｇ、香料０．０５ｋｇを配合し、２００ｍｌのレトルトパウチに充填し、レトルト殺菌機 (第１種圧力容器、ＴＹＰＥ: ＲＣＳ−４ＣＲＴＧＮ、日阪製作所製)で１２１℃、２０分間殺菌して、本発明の糖質代謝改善用液状栄養組成物５０ｋｇを製造した。 50 g of buttermilk of Example product 1 was dissolved in 4,950 g of deionized water, heated to 50 ° C., and then stirred at 6,000 rpm for 30 minutes with a TK homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.). Mixing gave a 50 g / 5 kg buttermilk solution. 5.0 kg of this buttermilk solution, 5.0 kg of casein, 5.0 kg of soy protein, 1.0 kg of fish oil, 3.0 kg of perilla oil, 17.0 kg of dextrin, 6.0 kg of mineral mixture, 1.95 kg of vitamin mixture, emulsifier 2 0.0kg, 4.0kg stabilizer, 0.05kg fragrance, filled in 200ml retort pouch, 121 ° C with retort sterilizer (first pressure vessel, TYPE: RCS-4CRTGN, manufactured by Nisaka Seisakusho) Sterilized for 20 minutes to produce 50 kg of the liquid nutrient composition for improving carbohydrate metabolism of the present invention.
脱脂粉乳３００ｇを４００ｇの脱イオン水に溶解した後、実施例品１のバターミルク１０ｇを溶解し、５０℃まで加熱後、ウルトラディスパーサー（ＵＬＴＲＡ−ＴＵＲＲＡＸ Ｔ−２５；ＩＫＡジャパン社製）にて、９，５００ｒｐｍで３０分間撹拌混合した。マルチトール１００ｇ、酸味料２ｇ、還元水飴２０ｇ、香料２ｇ、脱イオン水１６６ｇを添加した後、１００ｍｌのガラス瓶に充填し、９５℃、１５秒間殺菌後、密栓し、本発明の糖質代謝改善用飲料１０本（１００ｍｌ入り）を調製した。 After dissolving 300 g of skim milk powder in 400 g of deionized water, 10 g of buttermilk of Example Product 1 was dissolved, heated to 50 ° C., and then ultradispersed (ULTRA-TURRAX T-25; manufactured by IKA Japan). The mixture was stirred and mixed at 9,500 rpm for 30 minutes. 100 g maltitol, 2 g acidulant, 20 g reduced starch syrup, 2 g fragrance, 166 g deionized water, filled into a 100 ml glass bottle, sterilized at 95 ° C. for 15 seconds, sealed and used for improving carbohydrate metabolism of the present invention Ten drinks (with 100 ml) were prepared.
本発明の糖質吸収抑制剤や糖質代謝改善用飲食品は、これらを摂取することにより、消化管上皮細胞での糖質を抑制することで過剰な血糖値上昇を抑制することで、数々の生活習慣病の治療および予防に有効である。 The sugar absorption inhibitor and food / beverage product for improving carbohydrate metabolism of the present invention, by ingesting these, can suppress the excessive increase in blood glucose level by suppressing the sugar in the gastrointestinal epithelial cells. It is effective in the treatment and prevention of lifestyle-related diseases.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016050276A JP2017165661A (en) | 2016-03-14 | 2016-03-14 | Carbohydrate metabolism improver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016050276A JP2017165661A (en) | 2016-03-14 | 2016-03-14 | Carbohydrate metabolism improver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2017165661A true JP2017165661A (en) | 2017-09-21 |
Family
ID=59912594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016050276A Pending JP2017165661A (en) | 2016-03-14 | 2016-03-14 | Carbohydrate metabolism improver |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2017165661A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020002078A (en) * | 2018-06-29 | 2020-01-09 | キリンホールディングス株式会社 | Composition for improving exercise control function and exercise learning function |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007037413A1 (en) * | 2005-09-30 | 2007-04-05 | Morinaga Milk Industry Co., Ltd. | Agent for promoting glucagon-like peptide 1 secretion, food or drink for promoting glucagon-like peptide 1 secretion, agent for inhibiting postprandial increase in blood sugar level and food or drink for inhibiting postprandial increase in blood sugar level |
| JP2011144167A (en) * | 2009-12-18 | 2011-07-28 | Meiji Co Ltd | Hypoglycemic agent and hypoglycemic food and drink composition |
| WO2013129220A1 (en) * | 2012-03-02 | 2013-09-06 | 国立大学法人京都大学 | Pharmaceutical or food containing peptide |
| WO2015026245A1 (en) * | 2013-08-23 | 2015-02-26 | The A2 Milk Company Limited | Beta-casein a2 and blood glucose levels |
-
2016
- 2016-03-14 JP JP2016050276A patent/JP2017165661A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007037413A1 (en) * | 2005-09-30 | 2007-04-05 | Morinaga Milk Industry Co., Ltd. | Agent for promoting glucagon-like peptide 1 secretion, food or drink for promoting glucagon-like peptide 1 secretion, agent for inhibiting postprandial increase in blood sugar level and food or drink for inhibiting postprandial increase in blood sugar level |
| JP2011144167A (en) * | 2009-12-18 | 2011-07-28 | Meiji Co Ltd | Hypoglycemic agent and hypoglycemic food and drink composition |
| WO2013129220A1 (en) * | 2012-03-02 | 2013-09-06 | 国立大学法人京都大学 | Pharmaceutical or food containing peptide |
| WO2015026245A1 (en) * | 2013-08-23 | 2015-02-26 | The A2 Milk Company Limited | Beta-casein a2 and blood glucose levels |
Non-Patent Citations (3)
| Title |
|---|
| BAKHRU,H.K.: "11 Foods That Control Diabetes", CONQUERING DIABETES NATURALLY, JAN-1-2013, P.104, JPN7019004184, ISSN: 0004446086 * |
| DALAL,T.: "18. Nature Cures...Home Remedies for Diabetes", DELICIOUS DIABETIC RECIPES: LOW CALORIE COOKING, DEC-1-2005, P.43, JPN7019004185, ISSN: 0004446087 * |
| GILLE,D: "THE HEALTH ASPECTS OF BUTTERMILK COMPONENTS. A REVIEW.", ALP SCIENCE, 2011, NO.540, P.1-21, JPN6019051173, ISSN: 0004318012 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020002078A (en) * | 2018-06-29 | 2020-01-09 | キリンホールディングス株式会社 | Composition for improving exercise control function and exercise learning function |
| JP7139727B2 (en) | 2018-06-29 | 2022-09-21 | キリンホールディングス株式会社 | COMPOSITION FOR IMPROVING MOTOR CONTROL FUNCTION AND MOTOR LEARNING FUNCTION |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2648653C (en) | Fat accumulation inhibitor | |
| CN101415429B (en) | Lipopexia inhibitor | |
| JP2019528763A (en) | Novel Lactobacillus sakei and composition containing the same | |
| US20240115630A1 (en) | Bifidobacteria for reducing food, energy and/or fat intake | |
| JP5229977B2 (en) | Blood adiponectin concentration increase promoting and / or decreasing inhibitor | |
| JP4394155B2 (en) | Lipid metabolism improver | |
| JP7263426B2 (en) | obesity inhibitor | |
| CN107580496B (en) | Anti-diabetic effect of gypenoside 75 | |
| JP2012001516A (en) | Composition containing coix seed protein having lipid/carbohydrate metabolism improving action | |
| JP2008127364A (en) | Marker protein expression controlling agent | |
| JP2017165661A (en) | Carbohydrate metabolism improver | |
| JP2007254449A (en) | Lipid-improving agent | |
| JP6391959B2 (en) | Non-alcoholic steatohepatitis ameliorating agent and ameliorating nutrition composition | |
| JP2015164900A (en) | Sustained satiety agent and method for maintaining satisfaction | |
| JP4889970B2 (en) | Hyperphosphatemia preparation | |
| JP5087297B2 (en) | Interleukin-11 production promoter | |
| KR101697260B1 (en) | Composition Comprising Voglibose As a Prebiotic for Improving Intestinal Microflora or Preventing Obesity | |
| JP7660846B2 (en) | Capillary disorder inhibitor, capillary disorder improving agent, and capillary angiogenesis promoter | |
| JP5344669B2 (en) | Visceral fat accumulation inhibitor | |
| JP2007223926A (en) | Visceral fat accumulation depressor | |
| TW201825011A (en) | Composition for improving protein efficiency ratio | |
| JP2016204356A (en) | Hepatic fibrogenesis inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200422 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20200422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200805 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210217 |